

Notice of Revision of the Consolidated Earnings Forecast for the Fiscal Year Ending March 31, 2018

Company name: ROHTO Pharmaceutical Co., Ltd.
Representative: Toshiaki Yoshino, President and COO

Stock code: 4527

Stock Exchange listing: TSE, First Section
Contact: Masaya Saito, Director
Telephone: 81-(0) 6-6758-1211

1. Revision of Consolidated Earnings Forecast for the Six Months Ended September 30, 2017 (April 1, 2017 – September 30, 2017)

	Net sales	Operating	Ordinary	Profit attributable to	Net income
		income	income	owners of parent	per share
	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Yen
Forecast previously announced (A)	73,000	6,200	6,500	4,300	37.75
Revised forecast (B)	78,500	8,600	8,700	5,600	49.16
Change (B-A)	5,500	2,400	2,200	1,300	
Rate of change (%)	7.5	38.7	33.8	30.2	
(Ref.) Results for the six months ended September 30, 2016	71,298	6,465	6,822	4,191	36.83

2. Revision of Consolidated Earnings Forecast for the Fiscal Year Ending March 31, 2018 (April 1, 2017 – March 31, 2018)

	Net sales	Operating	Ordinary	Profit attributable to owners of parent	Net income per share
		income	income		
	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Yen
Forecast previously announced (A)	158,500	15,600	16,000	10,200	89.54
Revised forecast (B)	165,000	16,800	16,900	10,500	92.17
Change (B-A)	6,500	1,200	900	300	
Rate of change (%)	4.1	7.7	5.6	2.9	
(Ref.) Results for the year ended March 31, 2017	154,599	15,451	15,964	10,011	87.95